A Phase I Study of Dasatinib and Ipilimumab Immunotherapy for Patients with Advanced GIST or Other Sarcomas

Full Title

Phase I Study of Dasatinib in Combination with Ipilimumab for Patients with Advanced Gastrointestinal Stromal Tumor and Other Sarcomas (NCI #9172)


The purpose of this study is to find the optimal dose combination for the drugs dasatinib and ipilimumab to be used in patients with inoperable gastrointestinal stromal tumor (GIST) and other sarcomas.

Dasatinib is a drug used to treat chronic myelogenous leukemia that targets a protein known to also be involved in GIST growth. Ipilimumab is an immunotherapy drug approved for treating melanoma. It stimulates the immune system to fight cancer. The use of both drugs for treating sarcomas is considered investigational; laboratory studies have suggested that both drugs given together may be more effective against GIST than either one alone.

Dasatinib is a pill that is taken orally (by mouth), while ipilimumab is give intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic or inoperable GIST or other sarcoma that cannot be treated successfully using standard therapies and persists despite prior treatment.
  • At least 4 weeks must have passed since completion of prior chemotherapy, radiation therapy, or major surgery and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. William Tap at 646-888-4163.